AZE.US
Patients across Azerbaijan are increasingly hearing the same response at pharmacies: “It’s not available.”
For people living with chronic illnesses – particularly asthma and other respiratory conditions – the absence of prescribed medication is more than an inconvenience. It is a direct health risk.
Pharmacists confirm that some high-demand medicines have been difficult to find in recent weeks. While temporary substitutes are sometimes offered, any change must be approved by a physician. Under current regulations, pharmacists are not allowed to replace a prescribed drug without medical authorization.
At the same time, health authorities say no formal complaints about medication shortages have been officially registered.
The disconnect between patient experience and official reporting highlights deeper structural vulnerabilities.
What Is Disappearing?
According to pharmacy staff and patients:
-
Asthma inhalers and respiratory treatments
-
Certain long-term therapy medications
-
Selected high-demand chronic care drugs
In some cases, pharmacies promise delivery within 15–20 days. But delays persist, and patients often report visiting multiple locations without success.
Substitution is not always a simple solution. Even medications with similar active ingredients may differ in dosage form, absorption, or clinical effect. For chronic patients, abrupt changes can destabilize treatment.
Why Is This Happening?
1. Heavy Reliance on Imports
Azerbaijan’s pharmaceutical market is overwhelmingly dependent on imported medicines. Any disruption in international supply chains – whether due to geopolitical tensions, production delays, regulatory bottlenecks, or sanctions-related constraints – immediately affects domestic availability.
2. Currency and Payment Risks
Most pharmaceutical contracts are denominated in foreign currency. Exchange rate pressures, transaction barriers, or international banking complications can slow procurement or reduce shipment volumes.
3. Limited Import Channels
Only officially registered wholesale pharmaceutical companies are authorized to import medicines. While this system ensures regulatory oversight and quality control, it also reduces flexibility. If one supplier fails to deliver, alternative channels are not easily activated.
4. Weak Feedback Mechanism
Authorities state that no official shortage complaints have been filed. But many patients do not submit formal reports – they simply search for alternatives or rely on social media discussions. The absence of paperwork does not necessarily mean the absence of a problem.
A Structural Vulnerability
The issue may be temporary. Pharmaceutical supply chains can fluctuate, especially in periods of global uncertainty.
But the broader question remains: how resilient is a system that depends almost entirely on external production?
For patients managing chronic disease, even short-term supply gaps can trigger medical complications. For doctors, they require rapid treatment adjustments. For the healthcare system, recurring shortages signal structural exposure.
Azerbaijan’s pharmaceutical framework emphasizes regulation and safety oversight. The emerging challenge is ensuring continuity – especially when global supply pressures intensify.